HRH1

Histamine H1 receptor · P35367 · HRH1 on Sugi Atlas →

353,015 patent compounds predicted against HRH1, 225,544 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Mizolastine (SCHEMBL5061)	1.00	19/20
Rupatadine (SCHEMBL27703)	1.00	18/20
Azelastine (SCHEMBL4239)	1.00	17/20
Azelastine (SCHEMBL4240)	1.00	17/20
Azelastine (SCHEMBL36770)	1.00	17/20
Azelastine (SCHEMBL36771)	1.00	17/20
Desloratadine (SCHEMBL4425)	1.00	14/20
Epinastine (SCHEMBL18794)	0.45	13/20
Talastine (SCHEMBL30502)	0.81	9/20
Diisopromine (SCHEMBL25648)	0.63	9/20
Azatadine (SCHEMBL3721)	1.00	8/20
Loratadine (SCHEMBL4596)	1.00	8/20
Amitriptyline (SCHEMBL7824)	1.00	8/20
Dimethindene (SCHEMBL18759)	1.00	8/20
Cyclobenzaprine (SCHEMBL38527)	1.00	8/20
Prochlorperazine (SCHEMBL18429)	1.00	7/20
Nortriptyline (SCHEMBL34527)	1.00	7/20
Tolpropamine (SCHEMBL29300)	0.81	7/20
SCHEMBL38912	0.38	7/20
Fexofenadine (SCHEMBL4900)	1.00	6/20

Clinical trials — most relevant to HRH1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia	PHASE4	COMPLETED
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment	PHASE4	COMPLETED
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma	PHASE3	COMPLETED
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines	PHASE3	RECRUITING
Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria	PHASE3	UNKNOWN
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists	PHASE3	COMPLETED
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks	PHASE3	COMPLETED
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema	PHASE2/PHASE3	ENROLLING_BY_INVITATION
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.	PHASE3	NOT_YET_RECRUITING
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria	PHASE3	ACTIVE_NOT_RECRUITING
A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines	PHASE3	COMPLETED
Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines	PHASE2	COMPLETED
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria	PHASE2	NOT_YET_RECRUITING
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge	PHASE2	COMPLETED
A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria	PHASE2	UNKNOWN
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)	PHASE2	COMPLETED
A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria	PHASE2	UNKNOWN
Effects of Betahistine Hydrochloride in Overweight Women	PHASE1	COMPLETED
Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects	PHASE1	COMPLETED
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases	PHASE1	COMPLETED
A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases	PHASE1	COMPLETED
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer	nan	COMPLETED
The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients	nan	COMPLETED
The Efficacy in Treatment of Facial Melasma Combined With Thulium 1927-nm Fractional Laser and Topical H2R Antagonist	nan	COMPLETED
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy	nan	COMPLETED
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
Investigation of the Pruritogens of Liver-related Diseases	nan	UNKNOWN
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers	nan	COMPLETED
Dermal Blood Flow Response to Escalating Doses of Histamine, Administered by a Skin Prick	nan	COMPLETED
Histamine Responsiveness in McCune-Albright Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HRH1 binder may also engage these)

Protein	Name	Similarity
P31390	—	1.000	P31390 →
Q9N2B2	—	1.000	Q9N2B2 →
P70174	—	1.000	P70174 →
Q9N2B1	—	1.000	Q9N2B1 →
Q9N2B0	—	1.000	Q9N2B0 →
P31389	—	0.997	P31389 →
P30546	—	0.993	P30546 →
P18901	—	0.993	P18901 →
O42384	—	0.992	O42384 →
DRD2	D(2) dopamine receptor	0.992	landscape →
Q91081	—	0.991	Q91081 →
Q25322	—	0.991	Q25322 →
Q16950	—	0.990	Q16950 →
Q25321	—	0.990	Q25321 →
P50130	—	0.990	P50130 →
DRD1	D(1A) dopamine receptor	0.989	landscape →
P60026	—	0.989	P60026 →
O73810	—	0.989	O73810 →
P52702	—	0.989	P52702 →
P53453	—	0.989	P53453 →
Q8UUG8	—	0.989	Q8UUG8 →
Q91175	—	0.989	Q91175 →
Q19084	—	0.989	Q19084 →
P42288	—	0.989	P42288 →
P56490	—	0.989	P56490 →
Q6TLI9	—	0.988	Q6TLI9 →
Q95136	—	0.988	Q95136 →
P53452	—	0.988	P53452 →
Q6XXX9	—	0.988	Q6XXX9 →
Q02152	—	0.987	Q02152 →